Table 1.

Patient and tumor characteristics and uses in study

A. Patient cohort
Clinical conditionPatients (n)Primary useSecondary use
Training set424
Tis-T1*71Training set to developBCa-specific marker listTraining set to develop MI-BCa–specific marker list
T2-T4*56Training set to develop BCa-specific marker listTraining set to develop MI-BCa–specific marker list
Control set 1121Training set to develop BCa-specific marker list
Healthy volunteers110
Genitourinary disorders11
Control set 2176Quality set to develop BCa-specific marker list
Healthy volunteers142
Nephrolithiasis34
Test (validation) set130
Tis-T1*68Test set to evaluate MI-BCa
T2-4*62Test set to evaluate MI-BCa
Total554
B. Tumor characteristics of training and test set shown in A
StageParameterTraining setTest set
pTis-pT1n7168
Age (median/IQR)70126718
Gender (male/female)47244919
Tumor grade§ (low/high)51204226
T2-T4n5662
Age (median/IQR)65207013
Gender (male/female)34224715
Tumor grade§ (low/high)353359
  • *Bladder tumor stage (Sobin et al., 1997).

  • Disorders of the genitourinary tract such as cystitis, prostate cancer, or prostatism.

  • Bladder tumor stage (Sobin et al., 1997).

  • §Bladder tumor grade (Sauter et al., 2004).